Johnson & Johnson drug slows prostate cancer widespread by 58 percent: trial

<p>CHICAGO (Reuters) A hearing of Johnson Johnsons prostate cancer pill, Zytiga, found that it slowed a widespread of a illness by 58 percent in group who had stopped responding to hormonal drugs yet not nonetheless treated with chemotherapy, potentially charity new wish for patients who see their cancer return.
Zytiga is one of several new prostate cancer treatments that might significantly lengthen a life of patients by zeroing in some-more closely on certain mechanisms that assistance tumors proliferate. New information on a drugs are being presented during a American Society of Clinical Oncology (ASCO) annual assembly in Chicago.
The hearing of 1,088 prostate cancer patients showed those given a remedy and a steroid prednisone went a median of 8.3 months before their illness worsened. Patients treated with a steroid and Zytiga were still faring softened during a time a information were analyzed, so a allied statistic was not nonetheless available...